JP2007521313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007521313A5 JP2007521313A5 JP2006520139A JP2006520139A JP2007521313A5 JP 2007521313 A5 JP2007521313 A5 JP 2007521313A5 JP 2006520139 A JP2006520139 A JP 2006520139A JP 2006520139 A JP2006520139 A JP 2006520139A JP 2007521313 A5 JP2007521313 A5 JP 2007521313A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- amino
- compound according
- methoxyphenyl
- pyrrole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- -1 3-pyridylmethyl Chemical group 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000000069 prophylactic effect Effects 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 102000004311 liver X receptors Human genes 0.000 claims 2
- 108090000865 liver X receptors Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000004141 reverse cholesterol transport Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- MOHJWUULCVHTNF-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-(4-morpholin-4-ylanilino)-4-phenylpyrrole-2,5-dithione Chemical compound C1=NC(N)=CC=C1CN1C(=S)C(C=2C=CC=CC=2)=C(NC=2C=CC(=CC=2)N2CCOCC2)C1=S MOHJWUULCVHTNF-UHFFFAOYSA-N 0.000 claims 1
- JEJQEUJVUYOUSX-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-[4-(difluoromethoxy)anilino]-4-phenylpyrrole-2,5-dithione Chemical compound C1=NC(N)=CC=C1CN1C(=S)C(C=2C=CC=CC=2)=C(NC=2C=CC(OC(F)F)=CC=2)C1=S JEJQEUJVUYOUSX-UHFFFAOYSA-N 0.000 claims 1
- KCQCERDIYZAOTI-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-4-(4-morpholin-4-ylanilino)-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound C1=NC(N)=CC=C1CN1C(=S)C(NC=2C=CC(=CC=2)N2CCOCC2)=C(C=2C=CC=CC=2)C1=O KCQCERDIYZAOTI-UHFFFAOYSA-N 0.000 claims 1
- HKOGZAJTQNVYKL-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-4-[4-(difluoromethoxy)anilino]-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound C1=NC(N)=CC=C1CN1C(=S)C(NC=2C=CC(OC(F)F)=CC=2)=C(C=2C=CC=CC=2)C1=O HKOGZAJTQNVYKL-UHFFFAOYSA-N 0.000 claims 1
- IOIWSAHJOUDSRY-UHFFFAOYSA-N 1-benzyl-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dithione Chemical compound C1=CC(OC)=CC=C1NC(C1=S)=C(C=2C=CC=CC=2)C(=S)N1CC1=CC=CC=C1 IOIWSAHJOUDSRY-UHFFFAOYSA-N 0.000 claims 1
- LTTHEZOLSVUPKW-UHFFFAOYSA-N 1-benzyl-4-(4-methoxyanilino)-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound C1=CC(OC)=CC=C1NC(C1=S)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 LTTHEZOLSVUPKW-UHFFFAOYSA-N 0.000 claims 1
- YRKWCHDWFBAZKM-UHFFFAOYSA-N 1-butyl-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dithione Chemical compound C=1C=CC=CC=1C=1C(=S)N(CCCC)C(=S)C=1NC1=CC=C(OC)C=C1 YRKWCHDWFBAZKM-UHFFFAOYSA-N 0.000 claims 1
- SNZKVZCTAGKILF-UHFFFAOYSA-N 1-butyl-4-(4-methoxyanilino)-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound S=C1N(CCCC)C(=O)C(C=2C=CC=CC=2)=C1NC1=CC=C(OC)C=C1 SNZKVZCTAGKILF-UHFFFAOYSA-N 0.000 claims 1
- BYRPUFZFUOVSDM-UHFFFAOYSA-N 1-ethyl-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dithione Chemical compound C=1C=CC=CC=1C=1C(=S)N(CC)C(=S)C=1NC1=CC=C(OC)C=C1 BYRPUFZFUOVSDM-UHFFFAOYSA-N 0.000 claims 1
- SQUXAIADYPVBAH-UHFFFAOYSA-N 1-ethyl-4-(4-methoxyanilino)-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound S=C1N(CC)C(=O)C(C=2C=CC=CC=2)=C1NC1=CC=C(OC)C=C1 SQUXAIADYPVBAH-UHFFFAOYSA-N 0.000 claims 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- OYVJQJGUBFXSKH-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-(2-methoxyethyl)-4-phenylpyrrole-2,5-dithione Chemical compound C=1C=CC=CC=1C=1C(=S)N(CCOC)C(=S)C=1NC1=CC=C(OC)C=C1 OYVJQJGUBFXSKH-UHFFFAOYSA-N 0.000 claims 1
- ZEJARFJOUMEMPC-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-methyl-4-phenylpyrrole-2,5-dithione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=S)N(C)C1=S ZEJARFJOUMEMPC-UHFFFAOYSA-N 0.000 claims 1
- YZOJWRMGECTRBU-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrole-2,5-dithione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=S)N(CC(F)(F)F)C1=S YZOJWRMGECTRBU-UHFFFAOYSA-N 0.000 claims 1
- FVYSXHCRUKAQCM-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dithione Chemical compound C1=CC(OC)=CC=C1NC(C1=S)=C(C=2C=CC=CC=2)C(=S)N1CC1=CC=CN=C1 FVYSXHCRUKAQCM-UHFFFAOYSA-N 0.000 claims 1
- QDYXCIWVXFXUMP-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-4-ylmethyl)pyrrole-2,5-dithione Chemical compound C1=CC(OC)=CC=C1NC(C1=S)=C(C=2C=CC=CC=2)C(=S)N1CC1=CC=NC=C1 QDYXCIWVXFXUMP-UHFFFAOYSA-N 0.000 claims 1
- LWQZGNPYPZVZLJ-UHFFFAOYSA-N 4-(4-methoxyanilino)-1-(2-methoxyethyl)-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound S=C1N(CCOC)C(=O)C(C=2C=CC=CC=2)=C1NC1=CC=C(OC)C=C1 LWQZGNPYPZVZLJ-UHFFFAOYSA-N 0.000 claims 1
- IJRRWYZJKFXOMW-UHFFFAOYSA-N 4-(4-methoxyanilino)-1-methyl-3-phenyl-5-sulfanylidenepyrrol-2-one Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(C)C1=S IJRRWYZJKFXOMW-UHFFFAOYSA-N 0.000 claims 1
- XNIAFQVGGFMFMX-UHFFFAOYSA-N 4-(4-methoxyanilino)-3-phenyl-1-(pyridin-3-ylmethyl)-5-sulfanylidenepyrrol-2-one Chemical compound C1=CC(OC)=CC=C1NC(C1=S)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 XNIAFQVGGFMFMX-UHFFFAOYSA-N 0.000 claims 1
- MQFQGAMIOKBKSC-UHFFFAOYSA-N 4-(4-methoxyanilino)-3-phenyl-1-(pyridin-4-ylmethyl)-5-sulfanylidenepyrrol-2-one Chemical compound C1=CC(OC)=CC=C1NC(C1=S)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=NC=C1 MQFQGAMIOKBKSC-UHFFFAOYSA-N 0.000 claims 1
- CATPDSIFGQYWIV-UHFFFAOYSA-N 4-(4-methoxyanilino)-3-phenyl-5-sulfanylidene-1-(2,2,2-trifluoroethyl)pyrrol-2-one Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CC(F)(F)F)C1=S CATPDSIFGQYWIV-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940124358 agent for type 2 diabetes Drugs 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000033227 intestinal cholesterol absorption Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
| PCT/SE2004/001115 WO2005005416A1 (en) | 2003-07-11 | 2004-07-08 | Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007521313A JP2007521313A (ja) | 2007-08-02 |
| JP2007521313A5 true JP2007521313A5 (https=) | 2007-09-13 |
Family
ID=27741986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520139A Withdrawn JP2007521313A (ja) | 2003-07-11 | 2004-07-08 | 肝臓ｘ受容体モジュレーターとしてのピロール−２，５−ジチオン誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20060189663A1 (https=) |
| EP (1) | EP1646625B1 (https=) |
| JP (1) | JP2007521313A (https=) |
| KR (1) | KR20060034284A (https=) |
| CN (1) | CN100478340C (https=) |
| AR (1) | AR045720A1 (https=) |
| AT (1) | ATE399776T1 (https=) |
| AU (1) | AU2004256000B2 (https=) |
| BR (1) | BRPI0412479A (https=) |
| CA (1) | CA2532068A1 (https=) |
| CO (1) | CO5640134A2 (https=) |
| DE (1) | DE602004014772D1 (https=) |
| ES (1) | ES2308205T3 (https=) |
| GB (1) | GB0316237D0 (https=) |
| IL (1) | IL172759A0 (https=) |
| IS (1) | IS8291A (https=) |
| MX (1) | MXPA06000447A (https=) |
| NO (1) | NO20060080L (https=) |
| RU (1) | RU2006102129A (https=) |
| SA (1) | SA04250203B1 (https=) |
| TW (1) | TW200507836A (https=) |
| UA (1) | UA82108C2 (https=) |
| UY (1) | UY28407A1 (https=) |
| WO (1) | WO2005005416A1 (https=) |
| ZA (1) | ZA200600229B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
| CA2592771A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
| US7989179B2 (en) * | 2005-06-28 | 2011-08-02 | Daiichi Sankyo Company, Limited | LXR ligand testing method |
| ES2528797T3 (es) | 2006-08-21 | 2015-02-12 | Genentech, Inc. | Compuestos de aza-benzotiofenilo y métodos de uso |
| WO2008046014A1 (en) * | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
| US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
| WO2008103818A1 (en) * | 2007-02-21 | 2008-08-28 | University Of Louisville Research Foundation | Therapeutic cotinine compositions |
| PT2868315T (pt) | 2007-12-04 | 2017-09-04 | Remedy Pharmaceuticals Inc | Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos |
| US20110034560A1 (en) * | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| RU2509078C2 (ru) | 2008-07-01 | 2014-03-10 | Дженентек, Инк. | Бициклические гетероциклы в качестве ингибиторов киназы мек |
| MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
| US20130274212A1 (en) | 2010-09-07 | 2013-10-17 | Snu R&Db Foundation | Sesterterpene Compounds and Use Thereof |
| US10669296B2 (en) | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE284387T1 (de) * | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es not_active Expired - Lifetime
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en not_active Ceased
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Withdrawn
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 EP EP04749151A patent/EP1646625B1/en not_active Expired - Lifetime
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007521313A5 (https=) | ||
| RU2006102129A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| JP2007508360A5 (https=) | ||
| JP2007521312A5 (https=) | ||
| JP2005519083A5 (https=) | ||
| RU2741306C1 (ru) | Производные изоксазола в качестве агонистов ядерных рецепторов и их применение | |
| JP2007523155A5 (https=) | ||
| JP2003520235A5 (https=) | ||
| JP2006501295A5 (https=) | ||
| JP2005526723A5 (https=) | ||
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| JP2004506736A5 (https=) | ||
| JP2011505347A5 (https=) | ||
| JP2006506466A5 (https=) | ||
| RU2004113207A (ru) | Хинолиновые производные в качестве антагонистов нейропептида y | |
| TW201417811A (zh) | 脂質異常症治療劑 | |
| JP2007522135A5 (https=) | ||
| RU2006102130A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2004524279A5 (https=) | ||
| JP2020111571A5 (https=) | ||
| EP2139865B1 (en) | Solid forms of (e) -1- (4- ( (ir, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl) ethanone oxime | |
| JP2020534266A5 (https=) | ||
| JP2005513017A5 (https=) | ||
| RU2007116987A (ru) | Новые соединения |